Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients

Gómez, Henry L.; Castañeda, Carlos A.; Vigil, Carlos Enrique; Vidaurre, Tatiana; Velarde, R.; Cruz, Wilder R.; Pinto, Joseph A.; Suazo, Juan F.; Garcés, Milko; Neciosup, Silvia P.; Vallejos, Carlos S.

doi:10.1016/s1658-3876(10)50020-7

Cited by 13 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 25 ] showed that among metastatic breast cancer patients who were HER2+, more HR– patients benefited from trastuzumab treatment compared to HR+ patients. Our finding of greater OS for patients with HR+ status is consistent with several recent reports of various patient subsets [ 7 – 10 , 25 ]. Although HR+ status was favorable in comparison to HR– status according to univariate analysis, there was no significant difference in multivariate Cox proportional hazards regression analysis.…”

Section: Discussionsupporting

confidence: 93%

Clinicopathologic characteristics and prognostic factors for HER2-positive patients with metastatic breast cancer in southern China

Qin¹,

Yuan²,

Peng³

et al. 2015

aoms

View full text Add to dashboard Cite

IntroductionThe aim of the study was to analyze clinicopathologic characteristics and survival and to identify prognostic factors for Chinese patients with HER2-positive metastatic breast cancer.Material and methodsA total of 243 patients with HER2-positive metastatic breast cancer, treated during the period 2002 to 2009, were followed up from initial disease diagnosis to death or date of last follow-up (December 2011). Cumulative survival curves were created using Kaplan-Meier analysis with the log-rank test. Prognostic factors were analyzed by univariate and multivariate Cox proportional hazards regression analysis.ResultsDuring follow-up, 205 patients died, with a median OS of 27 months (95% CI: 23.5, 30.5 months), and the 1-, 3-, and 5-year survival rates were 84.4%, 38.6%, and 18.1%, respectively. The median OS of HR+ patients was significantly higher than that of HR– patients (p < 0.001). Surgery (hazard ratio = 0.60, p = 0.002), endocrine therapy (hazard ratio = 0.53, p < 0.01), and anti-HER2 therapy (hazard ratio = 0.63, p = 0.003) were favorable independent prognostic factors for patients with HER2-positive metastatic breast cancer.ConclusionsThese results indicated that surgical intervention, endocrine therapy, and anti-HER2 therapy were good for these HER2 positive patients with metastatic breast cancer, but ECOG performance status < 1 and metastasis to brain were unfavorable independent prognostic factors. HR status was not an independent prognostic factor.

show abstract

Section: Discussionsupporting

confidence: 93%

Clinicopathologic characteristics and prognostic factors for HER2-positive patients with metastatic breast cancer in southern China

Qin¹,

Yuan²,

Peng³

et al. 2015

aoms

View full text Add to dashboard Cite

show abstract

“…Variability in HR and HER2 results between institutions is an important issue and undefined criteria or variable cutoff values have been used in previous imaging studies on breast cancer subtypes (13). In our study, however, HR and HER2 positivity were defined according to the American Society of Clinical Oncology/College of American Pathologists guidelines (19,20) and our HR+ rate of 50.4% within HER2+ cancer was similar to rates of other studies (50–51.8%) (26,27). Second, the inter-observer variability in image interpretation was not assessed in this study.…”

Section: Discussionsupporting

confidence: 84%

MR and mammographic imaging features of HER2-positive breast cancers according to hormone receptor status: a retrospective comparative study

et al. 2016

View full text Add to dashboard Cite

Background Human epidermal growth factor receptor 2-positive (HER2+) breast cancer has two distinct subtypes according to hormone receptor (HR) status. Survival, pattern of recurrence, and treatment response differ between HR-/HER2+ and HR+/HER2+ cancers. Purpose To investigate imaging and clinicopathologic features of HER2+ cancers and their correlation with HR expression. Material and Methods Between 2011 and 2013, 252 consecutive patients with 252 surgically confirmed HER2+ cancers (125 HR- and 127 HR+) were included. Two experienced breast radiologists blinded to the clinicopathologic findings reviewed the mammograms and magnetic resonance (MR) images using the BI-RADS lexicon. Tumor kinetic features were acquired by computer-aided detection (CAD). The imaging and clinicopathologic features of 125 HR-/HER2+ cancers were compared with those of 127 HR+/HER2+ cancers. Association between the HR status and each feature was assessed. Results Multiple logistic regression analysis showed that circumscribed mass margin (odds ratio [OR], 4.73; P < 0.001), associated non-mass enhancement (NME) on MR images (OR, 3.29; P = 0.001), high histologic grade (OR, 3.89; P = 0.002), high Ki-67 index (OR, 3.06; P = 0.003), and older age (OR, 2.43; P = 0.006) remained independent indicators associated with HR-/HER2+ cancers. Between the two HER2+ subtypes, there were no differences in mammographic imaging presentations and calcification features and MR kinetic features by a CAD. Conclusion HER2+ breast cancers have different MR imaging (MRI) phenotypes and clinicopathologic feature according to HR status. MRI features related to HR and HER2 status have the potential to be used for the diagnosis and treatment decisions in HER2+ breast cancer patients.

show abstract

“…Although the 5‐year survival rate of BC is 90%, this disease remains the second most common cause of cancer‐related death, surpassed only by lung cancer in the United States. BC patients with ER‐positive or HER2‐positve disease have poor prognosis because of a high incidence of recurrence, metastasis, and resistance to current treatment modalities . Therefore, there is a need to identify therapeutic agents to combat the disease.…”

Section: Discussionmentioning

confidence: 99%

“…As compared to control, because of a high incidence of recurrence, metastasis, and resistance to current treatment modalities. 40 Therefore, there is a need to identify therapeutic agents to combat the disease. In this study, we investigated the ability of 2HF, natural bioactive product present in citrus fruits, in inhibiting BC growth in vitro and in vivo.…”

Section: Hf Inhibits Growth Of Tumors In Xenograft Mouse Models Ofmentioning

confidence: 99%

2′‐Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76

Singhal

Chikara

Horne

et al. 2018

Molecular Carcinogenesis

View full text Add to dashboard Cite

Consumption of citrus-fruits is associated with reduced incidence of breast cancer (BC), the most common cancer diagnosed in women across the globe. In this study, we investigated the anticancer potential of 2-Hydroxyflavanone (2HF) in BC. 2HF, a citrus-bioflavonoid, has demonstrated anticancer properties in various cancers, but its anticancer role in BC has not been well studied. We investigated the in vitro and in vivo growth inhibitory effects of 2HF in an array of BC lines and in xenograft mouse models of ER-positive and HER2-positive BC cells. Compared to control, 2HF treatment reduced cell viability and suppressed migratory and invasive potential of BC cells, while, no growth inhibitory effects were observed in non-tumorigenic breast epithelial cells. Further, 2HF inhibited the expression of RLIP76, a stress-defensive and anti-apoptotic protein, which is over-expressed in BC cells and simultaneously reduced proliferation of BC cells. Nude mice bearing MCF7 or SKBR3 BC cells xenografts treated with either 2HF or targeting RLIP76 by RLIP76-antisense or RLIP76-antibody treatment had significantly lower tumor-weight as compared to corresponding controls. In addition, Western-blotting and immunohistochemical analysis of tumor tissue from control and treatment group mice showed that 2HF decreased protein expression levels of RLIP76, and the decrease was similar to those seen following RLIP76-antisense treatment. Furthermore, 2HF decreased expression of Ki67, CD31, vimentin, inhibited phosphorylation of Akt and expression of survivin and Bcl2, and increased levels of Bax, E-cadherin, and cleaved-PARP. Therefore, our results indicate that 2HF may suppress BC growth in vitro and in vivo by targeting RLIP76, and may serve as a potential adjuvant treatment in BC patients.

show abstract

Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients

Abstract: Patients with (HER2+/ HR-) breast cancers treated with surgery and standard adjuvant chemotherapy exhibited a statistically worse DFS compared to those with (HER2+/ HR+) tumors. However, OS was similar in both groups.

Cited by 13 publications

References 18 publications

Clinicopathologic characteristics and prognostic factors for HER2-positive patients with metastatic breast cancer in southern China

Clinicopathologic characteristics and prognostic factors for HER2-positive patients with metastatic breast cancer in southern China

MR and mammographic imaging features of HER2-positive breast cancers according to hormone receptor status: a retrospective comparative study

2′‐Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76

Contact Info

Product

Resources

About